Related Experiment Video
Updated: May 13, 2026
05:23
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Intravenous Iron Repletion Does Not Significantly Decrease Platelet Counts in CKD Patients with Iron Deficiency
Neville R Dossabhoy1, Rebecca Gascoyne, Steven Turley
1Department of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA 71130-3932, USA ; Department of Medicine, Overton Brooks Veterans Affairs Medical Center, Shreveport, LA 71101, USA.
International Journal of Nephrology
|March 12, 2013
Summary
Intravenous iron repletion in chronic kidney disease (CKD) patients with iron deficiency anemia (IDA) did not significantly impact platelet counts. This study found no significant decrease in platelets after iron dextran total dose infusion (TDI).
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Iron deficiency anemia (IDA) is common in chronic kidney disease (CKD).
- Platelet (PLT) count alterations can occur in CKD patients.
- The effect of intravenous (IV) iron repletion on PLT counts in CKD-IDA requires further investigation.
Purpose of the Study:
- To investigate the impact of IV iron repletion on platelet counts in CKD patients with IDA.
- To determine if iron dextran total dose infusion (TDI) affects PLT levels in this population.
Main Methods:
- Retrospective chart review of CKD patients with IDA treated with iron dextran TDI between 2002 and 2007.
- Collected demographic and laboratory data including creatinine, hemoglobin (Hgb), iron stores, and PLT counts pre- and post-TDI.
- Analyzed data stratified by molecular weight (MW) and dose of iron dextran.
Main Results:
- 153 patients received 251 doses of iron dextran TDI.
- Hemoglobin and iron stores significantly improved post-TDI (P ≪ 0.001).
- A non-significant mild decrease in PLT counts was observed (pre-TDI 255 vs. post-TDI 244, P = 0.30), irrespective of iron dextran MW or dose.
Conclusions:
- Correction of iron deficiency with IV iron dextran TDI does not significantly lower platelet counts in CKD patients.
- The correlation between platelet counts and the severity of iron deficiency was weak.
- Clinical management of IDA in CKD patients with IV iron is unlikely to cause significant thrombocytopenia.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...